Akcea Therapeutics (AKCA) Misses Q1 EPS by 7c

Akcea Therapeutics (NASDAQ: AKCA) reported Q1 EPS of ($0.44), $0.07 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $17 million versus the consensus estimate of $12.12 million.

For earnings history and earnings-related data on Akcea Therapeutics (AKCA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• SanDisk upgraded at JPMorgan after investor day; shares climb